Examinando por Autor "Dianda, Daniela"
Mostrando 1 - 4 de 4
Resultados por página
Opciones de ordenación
Ítem El impacto de los cetoanálogos en la progresión de la nefropatía en pacientes mayores con enfermedad renal crónica avanzada(Ediciones Universidad Simón Bolívar, 2022) Sierra Pérez, Angelica María; Aroca Martínez, Gustavo; Musso, Carlos Guido; Dianda, DanielaLa enfermedad renal crónica (ERC) muestra un aumento en todo el mundo, y los pacientes de edad avanzada constituyen una proporción significativa y creciente de la población con ERC. La enfermedad renal en etapa terminal se puede tratar mediante la implementación de cuidados conservadores o terapias de reemplazo renal. La ERC se asocia con un mayor riesgo de progresión de la nefropatía, muerte por cualquier causa, muerte cardiovascular y daño renal agudo. Por tanto, el objetivo terapéutico de ralentizar la progresión de la ERC es crucial. La regulación de la ingesta proteica es el punto central del tratamiento nutricional en la ERC, y existe consenso en cuanto a su beneficio para retrasar la progresión de la ERC. Los cetoanálogos son análogos libres de nitrógeno de los aminoácidos esenciales que complementan las dietas bajas o muy bajas en proteínas. Se ha demostrado que estas dietas son eficaces para reducir la muerte renal en pacientes seleccionados con ERC. Por lo tanto, se decidió evaluar si la dieta cetogénica tenía beneficios para reducir la progresión de la ERC.Ítem Mortality rate and acute kidney injury prevalence reduction in COVID-19 critical patients treated with hemoperfusion(Wolters Kluwer, 2024) Barriga-Moreno, Adriana P.; Lozano Sánchez, Marcela; Barón-Álvarez, Rafael A.; Córdoba, Juan P.; Aroca-Martinez, Gustavo; Dianda, Daniela; González-Torres, Henry Joseth; Musso, CarlosIntroduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID‑19 treated with and without HPF with HA330 cartridge. Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID‑19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330. Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post‑HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group. Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID‑19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.Ítem Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion(Wolters Kluwer, 2024) Barriga‑Moreno, Adriana P.; Lozano‑Sánchez, Marcela; Barón‑Álvarez, Rafael A.; Cordoba, Juan P.; Aroca‑Martínez, Gustavo; Dianda, Daniela; Gonzalez‑Torres, Henry; Musso, Carlos G.Introduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID‑19 treated with and without HPF with HA330 cartridge. Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID‑19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330. Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post‑HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group. Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID‑19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.Ítem The Impact of Ketoanalogues on Nephropathy Progression in Advanced Chronic Kidney Disease Older Patients(Acta Scientific Publications, 2022) Aroca-Martinez, Gustavo; Sierra, Angélica; Barros-Camargo, Luis; Pertuz-Pinzon, Adolfo; Dianda, Daniela; Cadena-Bonfanti, Andrés; Musso, Carlos G.Advanced chronic kidney disease (CKD) can be treated with conservative care or renal replacement therapies. CKD is associated with an increased risk of nephropathy progression, and death. Therefore, slow down CKD progression is crucial, and there is consensus regarding protein intake regulation benefit in delaying this progression. Ketoanalogues are nitrogen-free analogs of essential amino acids which supplements low protein diets. Thus, it was decided to evaluate if keto diet had benefit in reducing CKD progression